Literature DB >> 16778115

Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency.

Jinsheng Yu, Howard L McLeod, Hany H Ezzeldin, Robert B Diasio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16778115     DOI： 10.1158/1078-0432.CCR-06-0549

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  8 in total

Review 1.  Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?

Authors:  Daniel Crona; Federico Innocenti
Journal:  Biomark Med       Date:  2012-06       Impact factor: 2.851

2.  Frequent intragenic rearrangements of DPYD in colorectal tumours.

Authors:  A B P van Kuilenburg; M-C Etienne-Grimaldi; A Mahamat; J Meijer; P Laurent-Puig; S Olschwang; M-P Gaub; R C M Hennekam; D Benchimol; S Houry; C Letoublon; F-N Gilly; D Pezet; T Andre; J-L Faucheron; A Abderrahim-Ferkoune; R Vijzelaar; B Pradere; G Milano
Journal:  Pharmacogenomics J       Date:  2014-10-28       Impact factor: 3.550

3.  Systems pharmacology assessment of the 5-fluorouracil pathway.

Authors:  Filipe A Muhale; Barbara A Wetmore; Russell S Thomas; Howard L McLeod
Journal:  Pharmacogenomics       Date:  2011-03       Impact factor: 2.533

Review 4.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

5.  DNA methylotype analysis in colorectal cancer.

Authors:  Jinsheng Yu; Robert R Freimuth; Robert Culverhouse; Sharon Marsh; Mark A Watson; Howard L McLeod
Journal:  Oncol Rep       Date:  2008-10       Impact factor: 3.906

6.  Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3.

Authors:  L Chen; C Hong; E C Chen; S W Yee; L Xu; E U Almof; C Wen; K Fujii; S J Johns; D Stryke; T E Ferrin; J Simko; X Chen; J F Costello; K M Giacomini
Journal:  Pharmacogenomics J       Date:  2012-01-10       Impact factor: 3.550

7.  The Clinical Significance of Promoter Methylation of Fluoropyrimidine Metabolizing and Cyclooxygenase Genes in Colorectal Cancer.

Authors:  Mariam Ahmed Fouad; Salem Eid Salem; Marwa M Hussien; Doaa Mohamed Badr; Abdelrahman N Zekri; Hafez Farouk Hafez; Samia A Shouman
Journal:  Epigenet Insights       Date:  2021-02-14

8.  Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?

Authors:  Marzia Del Re; Antonello Di Paolo; Ron H van Schaik; Guido Bocci; Paolo Simi; Alfredo Falcone; Romano Danesi
Journal:  EPMA J       Date:  2010-07-25       Impact factor: 6.543
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.